CV Therapeutics

CV Therapeutics Reviews

2 Reviews
2 Reviews

Recommend to a friend
Approve of CEO
CV Therapeutics CEO, Chief Science Officer, and Chairman Louis G. Lange
Louis G. Lange
1 Rating

    Cardiovascular Therapeutics, or any other molecule that looks promising…

    • Comp & Benefits
    • Work/Life Balance
    • Senior Management
    • Career Opportunities
    Current Employee - Anonymous Employee in Palo Alto, CA
    Current Employee - Anonymous Employee in Palo Alto, CA

    I have been working at CV Therapeutics


    Some very good people here, some interesting compounds in development.


    It's no longer clear that CV stands for "cardiovascular".

    Advice to ManagementAdvice

    Don't forget this company develops drugs for heart patients -- it's a limitation, but it's also a strength.

    No opinion of CEO

CV Therapeutics Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Headquarters Palo Alto, CA
Size 500 to 999 Employees
Founded Unknown
Type Subsidiary or Business Segment
Industry Biotech & Pharmaceuticals
Revenue $100 to $500 million (USD) per year

CV Therapeutics is more interested in Cardio Vascular drug research than fixing up résumés. The drug development company specializes in pharmaceuticals to treat chronic cardiovascular diseases. The firm's drug Ranexa, licensed from a Roche subsidiary, is FDA-approved as a first-line and second-line treatment for patients with chronic angina (chest pain). CV Therapeutics won approval for its cardiac imaging agent, Lexiscan, in 2008; the drug is marketed by Astellas Pharma. The company is developing additional potential therapies for ailments including heart failure and... More

Work at CV Therapeutics? Share Your Experiences

CV Therapeutics

Click to Rate